Professor Sandra O'Toole

Clinical Professor
Medicine, Central Clinical School

Telephone 95157182
Fax 951558405

Map

Biographical details

After graduating from Medicine from UNSW with the University Medal in 1997 and finishing my specialist training as a pathologist in 2003, I spent 2 years as a postdoctoral fellow at Johns Hopkins Hospital, completing my PhD in 2008 at the Garvan Institute of Medical Research. I currently divide my time between Royal Prince Alfred Hospital (as Staff Specialist in the Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and Head of Diagnostic Molecular Oncology) and the Garvan Institute of Medical Research as Head of Translational Breast Cancer Research.

I also head the diagnostic molecular oncology service at RPAH, the first comprehensive somatic mutation testing service in NSW to achieve NATA laboratory accreditation. This service has provided molecular pathology to guide the diagnosis and treatment of over 1500 patients with cancer.

Research interests

My research interest focuses on markers of breast cancer recurrence or progression in human tissues. I also have an interest in developmental pathways as potential novel therapeutic targets in breast cancer.

I am passionate about the translation of research into clinical practice, reflected in my clinical role as a molecular pathologist, integrating cutting edge technologies into the hospital setting. Much of my recent research concentrates on the application of molecular pathology to guide patient diagnosis and treatment selection.

Teaching and supervision

I currently supervise a number of honours, masters and a PhD student.

International links

United States

(McGill University Canada) Prof William Muller

United States

(University of Ohio) Prof Tsonwin Hai Professor College of Medicine

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Gibbings, K., Warrier, S., Hwang, S., Rice, M., O'Toole, S., Carmalt, H. (2014). A giant phyllodes tumour with sepsis. ANZ Journal of Surgery, 84(11), 886-887. [More Information]
  • Nair, R., Roden, D., Teo, W., McFarland, A., Junankar, S., Ye, S., Nguyen, A., Yang, J., Nicolic, I., Hui, M., Armstrong, N., Naylor, M., O'Toole, S., et al (2014). c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer. Oncogene, 33(30), 3992-4002. [More Information]
  • Kakavand, H., Crainic, O., Lum, T., O'Toole, S., Kefford, R., Thompson, J., Wilmott, J., Long, G., Scolyer, R. (2014). Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas. Pathology, 46(3), 193-198. [More Information]
  • Carlino, M., Haydu, L., Kakavand, H., Menzies, A., Hamilton, A., Yu, B., Ng, C., Cooper, W., Thompson, J., Kefford, R., O'Toole, S., Scolyer, R., Long, G. (2014). Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. British Journal of Cancer, 111(2), 292-299. [More Information]
  • Houang, M., Sioson, L., Clarkson, A., Watson, N., Mahtab, F., Toon, C., Raut, A., O'Toole, S., Cooper, W., Pavlakis, N., Gill, A., et al (2014). EGFR mutation specific immunohistochemistry is a useful adjunct which helps to identify false negative mutation testing in lung cancer. Pathology, 46(6), 501-508. [More Information]
  • Menzies, A., Lum, T., Wilmott, J., Hyman, J., Kefford, R., Thompson, J., O'Toole, S., Long, G., Scolyer, R. (2014). Intrapatient Homogeneity of BRAFV600E Expression in Melanoma. The American Journal of Surgical Pathology, 38(3), 377-382. [More Information]
  • Cooper, W., Fox, S., O'Toole, S., Morey, A., Frances, G., Pavlakis, N., OBrien, K., Dettrick, A., Leong, T., et al (2014). National Working Group Meeting on ALK diagnostics in lung cancer. Asia-Pacific Journal of Clinical Oncology, 12(SUPPL. 2), 11-17. [More Information]
  • Houang, M., Toon, C., Clarkson, A., Sioson, L., Watson, N., Farzin, M., Selinger, C., Chou, A., Morey, A., Cooper, W., O'Toole, S., Gill, A. (2014). Reflex ALK immunohistochemistry is feasible and highly specific for ALK gene rearrangements in lung cancer. Pathology, 46(5), 383-388. [More Information]
  • Schade, B., Lesurf, R., Sanguin-Gendreau, V., Bui, T., Deblois, G., O'Toole, S., Millar, E., Zardawi, S., Lopez-Knowles, E., Sutherland, R., et al (2013). B-Catenin Signaling is a Critical Event in ErbB2-Mediated Mammary Tumor Progression. Cancer Research, 73(14), 4474-4487. [More Information]
  • Klein, O., Clements, A., Menzies, A., O'Toole, S., Kefford, R., Long, G. (2013). BRAF inhibitor activity in V600R metastatic melanoma. European Journal of Cancer, 49(5), 1073-1079. [More Information]
  • Klein, O., Clements, A., Menzies, A., O'Toole, S., Kefford, R., Long, G. (2013). BRAF inhibitor activity in V600R metastatic melanoma – Response. European Journal of Cancer, 49(7), 1797-1798. [More Information]
  • O'Toole, S., Rakha, E., Ellis, I., Tan, P. (2013). Breast pathology today: morphology and molecules. Journal of Clinical Pathology, 66(6), 457. [More Information]
  • Cooper, C., O'Toole, S., Kench, J. (2013). Classification, morphology and molecular pathology of premalignant lesions of the pancreas. Pathology, 45(3), 286-304. [More Information]
  • Cooper, W., Yu, B., Yip, P., Ng, C., Lum, T., Farzin, M., Trent, R., Mercorella, B., Clarkson, A., Kohonen-Corish, M., Horvath, L., Kench, J., McCaughan, B., Gill, A., O'Toole, S. (2013). EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma. Journal of Clinical Pathology, 66(9), 744-748. [More Information]
  • Tran, T., Selinger, C., Kohonen-Corish, M., McCaughan, B., Kennedy, C., O'Toole, S., Cooper, W. (2013). Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer. Lung Cancer, 81(3), 462-467. [More Information]
  • Browne, B., Hochgrafe, F., Wu, J., Millar, E., Barraclough, J., Stone, A., McCloy, R., Lee, C., Roberts, C., Ali, N., O'Toole, S., et al (2013). Global characterization of signalling networks associated with tamoxifen resistance in breast cancer. The FEBS Journal, 280(21), 5237-5257. [More Information]
  • Cooper, C., Karim, R., Selinger, C., Carmalt, H., Lee, C., O'Toole, S. (2013). Molecular alterations in metaplastic breast carcinoma. Journal of Clinical Pathology, 66(6), 522-528. [More Information]
  • Cooper, W., Lam, D., O'Toole, S., Minna, J. (2013). Molecular biology of lung cancer. Journal of Thoracic Disease, 5(S5), S479-S490. [More Information]
  • Cooper, W., O'Toole, S. (2013). Molecular Pathology in lung Cancer. Cancer Forum, 37(2), 1-7.
  • Yip, P., Yu, B., Cooper, W., Selinger, C., Ng, C., Kennedy, C., Kohonen-Corish, M., McCaughan, B., Trent, R., Boyer, M., Kench, J., Horvath, L., O'Toole, S. (2013). Patterns of DNA mutations and ALK Rearrangement in Resected Node Negative Lung Adenocarcinoma. Journal of Thoracic Oncology, 8(4), 408-414. [More Information]
  • Saunderson, R., Garsia, R., Headley, A., McCaughan, G., O'Toole, S., Strasser, S. (2013). Pentoxifylline-induced drug rash with eosinophilia and systemic symptoms (DRESS) in a patient with caffeine intolerance. Journal of Dermatological Case Reports, 7(3), 77-81. [More Information]
  • Karim, R., O'Toole, S., Scolyer, R., Cooper, C., Chan, B., Selinger, C., Yu, B., Carmalt, H., Mak, C., Tse, G., Lee, C., et al (2013). Recent insights into the molecular pathogenesis of mammary phyllodes tumours. Journal of Clinical Pathology, 66(6), 496-505. [More Information]
  • Shields, B., Wiede, F., Gurzov, E., Wee, K., Hauser, C., Zhu, H., Molloy, T., O'Toole, S., Daly, R., Sutherland, R., et al (2013). TCPTP Regulates SFK and STAT3 Signaling and Is Lost in Triple-Negative Breast Cancers. Molecular and Cellular Biology, 33(3), 557-570. [More Information]
  • Selinger, C., Rogers, T., Russell, P., O'Toole, S., Yip, P., Wright, G., Wainer, Z., Horvath, L., Boyer, M., McCaughan, B., et al (2013). Testing for ALK rearrangement in lung adenocarcinoma: A multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Modern Pathology, 26(12), 1545-1553. [More Information]
  • Hui, M., Cazet, A., Nair, R., Watkins, D., O'Toole, S., Swarbrick, A. (2013). The Hedgehog signalling pathway in breast development, carcinogenesis and cancer therapy. Breast Cancer Research, 15(2), 1-14. [More Information]
  • O'Toole, S., Beith, J., Millar, E., West, R., McLean, A., Cazet, A., Swarbrick, A., Oakes, S. (2013). Therapeutic targets in triple negative breast cancer. Journal of Clinical Pathology, 66(6), 530-542. [More Information]
  • Coates, A., Millar, E., O'Toole, S., Molloy, T., Viale, G., Goldhirsch, A., Regan, M., Gelber, R., Sun, Z., Castiglione-Gertsch, M., et al (2012). Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX. Breast Cancer Research, 14(6), 1-12. [More Information]
  • Xu, H., Yan, M., Patra, J., Natrajan, R., Yan, Y., Swagemakers, S., Tomaszewski, J., Verschoor, S., Millar, E., van der Spek, P., O'Toole, S., McNeil, C., et al (2011). Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers. Breast Cancer Research, 13(1), R9-1-R9-36. [More Information]
  • O'Toole, S., Machalek, D., Shearer, R., Millar, E., Nair, R., Schofield, P., McLeod, D., Cooper, C., McNeil, C., McFarland, A., et al (2011). Hedgehog Overexpression Is Associated with Stromal Interactions and Predicts for Poor Outcome in Breast Cancer. Cancer Research, 71(11), 4002-4014. [More Information]
  • Roberts, C., Millar, E., O'Toole, S., McNeil, C., Lehrbach, G., Pinese, M., Tobelmann, P., McCloy, R., Musgrove, E., Sutherland, R., et al (2011). Identification of PUMA as an estrogen target gene that mediates the apoptotic response to tamoxifen in human breast cancer cells and predicts patient outcome and tamoxifen responsiveness in breast cancer. Oncogene, 30(28), 3186-3197. [More Information]
  • O'Toole, S., Selinger, C., Millar, E., Lum, T., Beith, J. (2011). Molecular assays in breast cancer pathology. Pathology, 43(2), 116-127. [More Information]
  • Millar, E., Graham, P., McNeil, C., Browne, L., O'Toole, S., Boulghourjian, A., Kearsley, J., Papadatos, G., Delaney, G., Fox, C., et al (2011). Prediction of outcome of early ER + breast cancer is improved using a biomarker panel, which includes Ki-67 and p53. British Journal of Cancer, 105(2), 272-280. [More Information]
  • Colvin, E., Susanto, J., Kench, J., Ong, V., Mawson, A., Pinese, M., Chang, D., Rooman, I., O'Toole, S., Segara, D., et al (2011). Retinoid signaling in pancreatic cancer, injury and regeneration. PloS One, 6(12), e29075 - 1-e29075 - 10. [More Information]
  • Chan, P., Möller, A., Liu, M., Sceneay, J., Wong, C., Waddell, N., Huang, K., Dobrovic, A., Millar, E., O'Toole, S., et al (2011). The expression of the ubiquitin ligase SIAH2 (seven in absentia homolog 2) is mediated through gene copy number in breast cancer and is associated with a basal-like phenotype and p53 expression. Breast Cancer Research, 13(1), 1-10. [More Information]
  • Cooper, W., O'Toole, S., Boyer, M., Horvath, L., Mahar, A. (2011). What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements. Pathology, 43(2), 103-115. [More Information]
  • Lopez-Knowles, E., Zardawi, S., McNeil, C., Millar, E., Crea, P., Musgrove, E., Sutherland, R., O'Toole, S. (2010). Cytoplasmic Localization of beta-Catenin is a Marker of Poor Outcome in Breast Cancer Patients. Cancer Epidemiology, Biomarkers and Prevention, 19(1), 301-309. [More Information]
  • Zardawi, S., Zardawi, I., McNeil, C., Millar, E., McLeod, D., Morey, A., Crea, P., Murphy, N., Pinese, M., Lopez-Knowles, E., Hamilton, A., Spillane, A., Lee, C., et al (2010). High Notch1 protein expression is an early event in breast cancer development and is associated with the HER-2 molecular subtype. Histopathology, 56(3), 286-296. [More Information]
  • Murphy, N., Biankin, A., Millar, E., McNeil, C., O'Toole, S., Segara, D., Crea, P., Olayioye, M., Lee, C., Fox, S., et al (2010). Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status. International Journal of Cancer, 126(6), 1445-1453. [More Information]
  • Fleuren, E., O'Toole, S., Millar, E., McNeil, C., Lopez-Knowles, E., Boulghourjian, A., Croucher, D., Schramek, D., Brummer, T., Penninger, J., et al (2010). Overexpression of the oncogenic signal transducer Gab2 occurs early in breast cancer development. International Journal of Cancer, 127(6), 1486-92. [More Information]
  • Lopez-Knowles, E., O'Toole, S., McNeil, C., Millar, E., Qiu, M., Crea, P., Daly, R., Musgrove, E., Sutherland, R. (2010). PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. International Journal of Cancer, 126(5), 1121-1131. [More Information]
  • Nair, R., Junankar, S., O'Toole, S., Shah, J., Borowsky, A., Bishop, J., Swarbrick, A. (2010). Redefining the expression and function of the inhibitor of differentiation 1 in mammary gland development. PloS One, 5(8), 1-7. [More Information]
  • Palmer, C., Corpuz, T., Marianne, G., O'Toole, S., Yan, K., Bu, Y., Jorgenson, J., Talbot, M., Loi, K., Lloyd, A., et al (2010). The effect of obesity on intrahepatic cytokine and chemokine expression in chronic hepatitis c infection. Gut (English Edition): an international journal of gastroenterology and hepatology, 59, 397-404. [More Information]
  • Hochgrafe, F., Zhang, L., O'Toole, S., Browne, B., Pinese, M., Cubas, A., Lehrbach, G., Lehrbach, D., Rickwood, D., Boulghourjian, A. (2010). Tyrosine Phosphorylation Profiling Reveals the Signaling Network Characteristics of Basal Breast Cancer Cells. Cancer Research, 70(22), 9391-9401. [More Information]
  • Millar, E., Anderson, L., McNeil, C., O'Toole, S., Pinese, M., Crea, P., Morey, A., Biankin, A., Henshall, S., Musgrove, E., et al (2009). BAG-1 predicts patient outcome and tamoxifen responsiveness in ER-positive invasive ductal carcinoma of the breast. British Journal of Cancer, 100(1), 123-133. [More Information]
  • Millar, E., Dean, J., McNeil, C., O'Toole, S., Henshall, S., Lin, J., Quong, A., Comstock, C., Witkiewicz, A., Musgrove, E., et al (2009). Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome. Oncogene, 28(15), 1812-1820. [More Information]
  • Zhang, J., O'Toole, S., Sutherland, R., Musgrove, E. (2009). Dysregulation of Hedgehog, Wnt and Notch signalling pathways in breast cancer. Histology and histopathology, 24(3), 385-398. [More Information]
  • Kitzing, B., O'Toole, S., Waugh, A., Clayton, J., McGill, N., Allman, K. (2009). Hepatobiliary scintigraphy in vasculitis of the gallbladder as a manifestation of polyarteritis nodosa: a case report. Cases Journal, 2, 9300. [More Information]
  • Millar, E., Graham, P., O'Toole, S., McNeil, C., Browne, L., Morey, A., Eggleton, S., Beretov, J., Theocharous, C., Capp, A. (2009). Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. Journal of Clinical Oncology, 27(28), 4701-4708. [More Information]
  • O'Toole, S., Swarbrick, A., Sutherland, R. (2009). The Hedgehog signalling pathway as a therapeutic target in early breast cancer development. Expert Opinion on Therapeutic Targets, 13(9), 1095-1103. [More Information]
  • Tan, E., Yan, M., Campo, L., Han, C., Takano, E., Turley, H., Candiloro, I., Pezzela, F., Gatter, K., Millar, E., O'Toole, S., et al (2009). The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. British Journal of Cancer, 100(2), 405-411. [More Information]

2014

  • Gibbings, K., Warrier, S., Hwang, S., Rice, M., O'Toole, S., Carmalt, H. (2014). A giant phyllodes tumour with sepsis. ANZ Journal of Surgery, 84(11), 886-887. [More Information]
  • Nair, R., Roden, D., Teo, W., McFarland, A., Junankar, S., Ye, S., Nguyen, A., Yang, J., Nicolic, I., Hui, M., Armstrong, N., Naylor, M., O'Toole, S., et al (2014). c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer. Oncogene, 33(30), 3992-4002. [More Information]
  • Kakavand, H., Crainic, O., Lum, T., O'Toole, S., Kefford, R., Thompson, J., Wilmott, J., Long, G., Scolyer, R. (2014). Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas. Pathology, 46(3), 193-198. [More Information]
  • Carlino, M., Haydu, L., Kakavand, H., Menzies, A., Hamilton, A., Yu, B., Ng, C., Cooper, W., Thompson, J., Kefford, R., O'Toole, S., Scolyer, R., Long, G. (2014). Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. British Journal of Cancer, 111(2), 292-299. [More Information]
  • Houang, M., Sioson, L., Clarkson, A., Watson, N., Mahtab, F., Toon, C., Raut, A., O'Toole, S., Cooper, W., Pavlakis, N., Gill, A., et al (2014). EGFR mutation specific immunohistochemistry is a useful adjunct which helps to identify false negative mutation testing in lung cancer. Pathology, 46(6), 501-508. [More Information]
  • Menzies, A., Lum, T., Wilmott, J., Hyman, J., Kefford, R., Thompson, J., O'Toole, S., Long, G., Scolyer, R. (2014). Intrapatient Homogeneity of BRAFV600E Expression in Melanoma. The American Journal of Surgical Pathology, 38(3), 377-382. [More Information]
  • Cooper, W., Fox, S., O'Toole, S., Morey, A., Frances, G., Pavlakis, N., OBrien, K., Dettrick, A., Leong, T., et al (2014). National Working Group Meeting on ALK diagnostics in lung cancer. Asia-Pacific Journal of Clinical Oncology, 12(SUPPL. 2), 11-17. [More Information]
  • Houang, M., Toon, C., Clarkson, A., Sioson, L., Watson, N., Farzin, M., Selinger, C., Chou, A., Morey, A., Cooper, W., O'Toole, S., Gill, A. (2014). Reflex ALK immunohistochemistry is feasible and highly specific for ALK gene rearrangements in lung cancer. Pathology, 46(5), 383-388. [More Information]

2013

  • Schade, B., Lesurf, R., Sanguin-Gendreau, V., Bui, T., Deblois, G., O'Toole, S., Millar, E., Zardawi, S., Lopez-Knowles, E., Sutherland, R., et al (2013). B-Catenin Signaling is a Critical Event in ErbB2-Mediated Mammary Tumor Progression. Cancer Research, 73(14), 4474-4487. [More Information]
  • Klein, O., Clements, A., Menzies, A., O'Toole, S., Kefford, R., Long, G. (2013). BRAF inhibitor activity in V600R metastatic melanoma. European Journal of Cancer, 49(5), 1073-1079. [More Information]
  • Klein, O., Clements, A., Menzies, A., O'Toole, S., Kefford, R., Long, G. (2013). BRAF inhibitor activity in V600R metastatic melanoma – Response. European Journal of Cancer, 49(7), 1797-1798. [More Information]
  • O'Toole, S., Rakha, E., Ellis, I., Tan, P. (2013). Breast pathology today: morphology and molecules. Journal of Clinical Pathology, 66(6), 457. [More Information]
  • Cooper, C., O'Toole, S., Kench, J. (2013). Classification, morphology and molecular pathology of premalignant lesions of the pancreas. Pathology, 45(3), 286-304. [More Information]
  • Cooper, W., Yu, B., Yip, P., Ng, C., Lum, T., Farzin, M., Trent, R., Mercorella, B., Clarkson, A., Kohonen-Corish, M., Horvath, L., Kench, J., McCaughan, B., Gill, A., O'Toole, S. (2013). EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma. Journal of Clinical Pathology, 66(9), 744-748. [More Information]
  • Tran, T., Selinger, C., Kohonen-Corish, M., McCaughan, B., Kennedy, C., O'Toole, S., Cooper, W. (2013). Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer. Lung Cancer, 81(3), 462-467. [More Information]
  • Browne, B., Hochgrafe, F., Wu, J., Millar, E., Barraclough, J., Stone, A., McCloy, R., Lee, C., Roberts, C., Ali, N., O'Toole, S., et al (2013). Global characterization of signalling networks associated with tamoxifen resistance in breast cancer. The FEBS Journal, 280(21), 5237-5257. [More Information]
  • Cooper, C., Karim, R., Selinger, C., Carmalt, H., Lee, C., O'Toole, S. (2013). Molecular alterations in metaplastic breast carcinoma. Journal of Clinical Pathology, 66(6), 522-528. [More Information]
  • Cooper, W., Lam, D., O'Toole, S., Minna, J. (2013). Molecular biology of lung cancer. Journal of Thoracic Disease, 5(S5), S479-S490. [More Information]
  • Cooper, W., O'Toole, S. (2013). Molecular Pathology in lung Cancer. Cancer Forum, 37(2), 1-7.
  • Yip, P., Yu, B., Cooper, W., Selinger, C., Ng, C., Kennedy, C., Kohonen-Corish, M., McCaughan, B., Trent, R., Boyer, M., Kench, J., Horvath, L., O'Toole, S. (2013). Patterns of DNA mutations and ALK Rearrangement in Resected Node Negative Lung Adenocarcinoma. Journal of Thoracic Oncology, 8(4), 408-414. [More Information]
  • Saunderson, R., Garsia, R., Headley, A., McCaughan, G., O'Toole, S., Strasser, S. (2013). Pentoxifylline-induced drug rash with eosinophilia and systemic symptoms (DRESS) in a patient with caffeine intolerance. Journal of Dermatological Case Reports, 7(3), 77-81. [More Information]
  • Karim, R., O'Toole, S., Scolyer, R., Cooper, C., Chan, B., Selinger, C., Yu, B., Carmalt, H., Mak, C., Tse, G., Lee, C., et al (2013). Recent insights into the molecular pathogenesis of mammary phyllodes tumours. Journal of Clinical Pathology, 66(6), 496-505. [More Information]
  • Shields, B., Wiede, F., Gurzov, E., Wee, K., Hauser, C., Zhu, H., Molloy, T., O'Toole, S., Daly, R., Sutherland, R., et al (2013). TCPTP Regulates SFK and STAT3 Signaling and Is Lost in Triple-Negative Breast Cancers. Molecular and Cellular Biology, 33(3), 557-570. [More Information]
  • Selinger, C., Rogers, T., Russell, P., O'Toole, S., Yip, P., Wright, G., Wainer, Z., Horvath, L., Boyer, M., McCaughan, B., et al (2013). Testing for ALK rearrangement in lung adenocarcinoma: A multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Modern Pathology, 26(12), 1545-1553. [More Information]
  • Hui, M., Cazet, A., Nair, R., Watkins, D., O'Toole, S., Swarbrick, A. (2013). The Hedgehog signalling pathway in breast development, carcinogenesis and cancer therapy. Breast Cancer Research, 15(2), 1-14. [More Information]
  • O'Toole, S., Beith, J., Millar, E., West, R., McLean, A., Cazet, A., Swarbrick, A., Oakes, S. (2013). Therapeutic targets in triple negative breast cancer. Journal of Clinical Pathology, 66(6), 530-542. [More Information]

2012

  • Coates, A., Millar, E., O'Toole, S., Molloy, T., Viale, G., Goldhirsch, A., Regan, M., Gelber, R., Sun, Z., Castiglione-Gertsch, M., et al (2012). Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX. Breast Cancer Research, 14(6), 1-12. [More Information]

2011

  • Xu, H., Yan, M., Patra, J., Natrajan, R., Yan, Y., Swagemakers, S., Tomaszewski, J., Verschoor, S., Millar, E., van der Spek, P., O'Toole, S., McNeil, C., et al (2011). Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers. Breast Cancer Research, 13(1), R9-1-R9-36. [More Information]
  • O'Toole, S., Machalek, D., Shearer, R., Millar, E., Nair, R., Schofield, P., McLeod, D., Cooper, C., McNeil, C., McFarland, A., et al (2011). Hedgehog Overexpression Is Associated with Stromal Interactions and Predicts for Poor Outcome in Breast Cancer. Cancer Research, 71(11), 4002-4014. [More Information]
  • Roberts, C., Millar, E., O'Toole, S., McNeil, C., Lehrbach, G., Pinese, M., Tobelmann, P., McCloy, R., Musgrove, E., Sutherland, R., et al (2011). Identification of PUMA as an estrogen target gene that mediates the apoptotic response to tamoxifen in human breast cancer cells and predicts patient outcome and tamoxifen responsiveness in breast cancer. Oncogene, 30(28), 3186-3197. [More Information]
  • O'Toole, S., Selinger, C., Millar, E., Lum, T., Beith, J. (2011). Molecular assays in breast cancer pathology. Pathology, 43(2), 116-127. [More Information]
  • Millar, E., Graham, P., McNeil, C., Browne, L., O'Toole, S., Boulghourjian, A., Kearsley, J., Papadatos, G., Delaney, G., Fox, C., et al (2011). Prediction of outcome of early ER + breast cancer is improved using a biomarker panel, which includes Ki-67 and p53. British Journal of Cancer, 105(2), 272-280. [More Information]
  • Colvin, E., Susanto, J., Kench, J., Ong, V., Mawson, A., Pinese, M., Chang, D., Rooman, I., O'Toole, S., Segara, D., et al (2011). Retinoid signaling in pancreatic cancer, injury and regeneration. PloS One, 6(12), e29075 - 1-e29075 - 10. [More Information]
  • Chan, P., Möller, A., Liu, M., Sceneay, J., Wong, C., Waddell, N., Huang, K., Dobrovic, A., Millar, E., O'Toole, S., et al (2011). The expression of the ubiquitin ligase SIAH2 (seven in absentia homolog 2) is mediated through gene copy number in breast cancer and is associated with a basal-like phenotype and p53 expression. Breast Cancer Research, 13(1), 1-10. [More Information]
  • Cooper, W., O'Toole, S., Boyer, M., Horvath, L., Mahar, A. (2011). What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements. Pathology, 43(2), 103-115. [More Information]

2010

  • Lopez-Knowles, E., Zardawi, S., McNeil, C., Millar, E., Crea, P., Musgrove, E., Sutherland, R., O'Toole, S. (2010). Cytoplasmic Localization of beta-Catenin is a Marker of Poor Outcome in Breast Cancer Patients. Cancer Epidemiology, Biomarkers and Prevention, 19(1), 301-309. [More Information]
  • Zardawi, S., Zardawi, I., McNeil, C., Millar, E., McLeod, D., Morey, A., Crea, P., Murphy, N., Pinese, M., Lopez-Knowles, E., Hamilton, A., Spillane, A., Lee, C., et al (2010). High Notch1 protein expression is an early event in breast cancer development and is associated with the HER-2 molecular subtype. Histopathology, 56(3), 286-296. [More Information]
  • Murphy, N., Biankin, A., Millar, E., McNeil, C., O'Toole, S., Segara, D., Crea, P., Olayioye, M., Lee, C., Fox, S., et al (2010). Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status. International Journal of Cancer, 126(6), 1445-1453. [More Information]
  • Fleuren, E., O'Toole, S., Millar, E., McNeil, C., Lopez-Knowles, E., Boulghourjian, A., Croucher, D., Schramek, D., Brummer, T., Penninger, J., et al (2010). Overexpression of the oncogenic signal transducer Gab2 occurs early in breast cancer development. International Journal of Cancer, 127(6), 1486-92. [More Information]
  • Lopez-Knowles, E., O'Toole, S., McNeil, C., Millar, E., Qiu, M., Crea, P., Daly, R., Musgrove, E., Sutherland, R. (2010). PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. International Journal of Cancer, 126(5), 1121-1131. [More Information]
  • Nair, R., Junankar, S., O'Toole, S., Shah, J., Borowsky, A., Bishop, J., Swarbrick, A. (2010). Redefining the expression and function of the inhibitor of differentiation 1 in mammary gland development. PloS One, 5(8), 1-7. [More Information]
  • Palmer, C., Corpuz, T., Marianne, G., O'Toole, S., Yan, K., Bu, Y., Jorgenson, J., Talbot, M., Loi, K., Lloyd, A., et al (2010). The effect of obesity on intrahepatic cytokine and chemokine expression in chronic hepatitis c infection. Gut (English Edition): an international journal of gastroenterology and hepatology, 59, 397-404. [More Information]
  • Hochgrafe, F., Zhang, L., O'Toole, S., Browne, B., Pinese, M., Cubas, A., Lehrbach, G., Lehrbach, D., Rickwood, D., Boulghourjian, A. (2010). Tyrosine Phosphorylation Profiling Reveals the Signaling Network Characteristics of Basal Breast Cancer Cells. Cancer Research, 70(22), 9391-9401. [More Information]

2009

  • Millar, E., Anderson, L., McNeil, C., O'Toole, S., Pinese, M., Crea, P., Morey, A., Biankin, A., Henshall, S., Musgrove, E., et al (2009). BAG-1 predicts patient outcome and tamoxifen responsiveness in ER-positive invasive ductal carcinoma of the breast. British Journal of Cancer, 100(1), 123-133. [More Information]
  • Millar, E., Dean, J., McNeil, C., O'Toole, S., Henshall, S., Lin, J., Quong, A., Comstock, C., Witkiewicz, A., Musgrove, E., et al (2009). Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome. Oncogene, 28(15), 1812-1820. [More Information]
  • Zhang, J., O'Toole, S., Sutherland, R., Musgrove, E. (2009). Dysregulation of Hedgehog, Wnt and Notch signalling pathways in breast cancer. Histology and histopathology, 24(3), 385-398. [More Information]
  • Kitzing, B., O'Toole, S., Waugh, A., Clayton, J., McGill, N., Allman, K. (2009). Hepatobiliary scintigraphy in vasculitis of the gallbladder as a manifestation of polyarteritis nodosa: a case report. Cases Journal, 2, 9300. [More Information]
  • Millar, E., Graham, P., O'Toole, S., McNeil, C., Browne, L., Morey, A., Eggleton, S., Beretov, J., Theocharous, C., Capp, A. (2009). Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. Journal of Clinical Oncology, 27(28), 4701-4708. [More Information]
  • O'Toole, S., Swarbrick, A., Sutherland, R. (2009). The Hedgehog signalling pathway as a therapeutic target in early breast cancer development. Expert Opinion on Therapeutic Targets, 13(9), 1095-1103. [More Information]
  • Tan, E., Yan, M., Campo, L., Han, C., Takano, E., Turley, H., Candiloro, I., Pezzela, F., Gatter, K., Millar, E., O'Toole, S., et al (2009). The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. British Journal of Cancer, 100(2), 405-411. [More Information]

To update your profile click here. For support on your academic profile contact .